A bone-targeting drug delivery vehicle of a metal–organic framework conjugate with zoledronate combined with photothermal therapy for tumor inhibition in cancer bone metastasis. (7th March 2022)
- Record Type:
- Journal Article
- Title:
- A bone-targeting drug delivery vehicle of a metal–organic framework conjugate with zoledronate combined with photothermal therapy for tumor inhibition in cancer bone metastasis. (7th March 2022)
- Main Title:
- A bone-targeting drug delivery vehicle of a metal–organic framework conjugate with zoledronate combined with photothermal therapy for tumor inhibition in cancer bone metastasis
- Authors:
- Ge, Ting
Weiwei, Zhang
Ge, Fei
Zhu, Longbao
Song, Ping
Li, Wanzheng
Gui, Lin
Dong, Wan
Tao, Yugui
Yang, Kai - Abstract:
- Abstract : Synthesis of 5-Fu/ICG@ZIF-90-PEG-ZOL. Design based on bone-targeted modification on the surface of nanocarrier with ZOL, and also in combination chemotherapy and photothermal therapy (created in BioRender.com). Abstract : Chemotherapy is a conventional treatment method for metastatic bone cancer, but it has limitations, such as lower drug-targeting of bone tissues and serious side effects. Bone metastasis almost always occurs in advanced cancer, and most patients in this period have strong drug resistance, which further worsens the curative effect. To address the above-mentioned difficulties, a drug delivery platform is proposed in this paper that accomplishes the bone-targeting of drugs to efficiently inhibit tumors. First, the anti-cancer drugs 5-fluorouracil (5-Fu) and indocyanine green (ICG) were loaded into a zeolitic imidazolate framework (ZIF-90) to form 5-Fu/ICG@ZIF-90. Polyethylene glycol with zoledronic acid (ZOL) was encapsulated using 5-Fu/ICG@ZIF-90 to synthesize 5-Fu/ICG@ZIF-90-PEG-ZOL nanoparticles, which showed dimensional stability, good thermal stability, and bone-targeting ability. Second, the in vitro anti-cancer activity of the designed platform was investigated using cytotoxicity, apoptosis, live–dead staining, cell cycle, and cell ultrathin section analysis. The results indicated that the nanoparticles inhibited MCF-7 cell activity when chemotherapy was combined with PTT. Finally, H&E staining and TUNEL detection were performed in mouseAbstract : Synthesis of 5-Fu/ICG@ZIF-90-PEG-ZOL. Design based on bone-targeted modification on the surface of nanocarrier with ZOL, and also in combination chemotherapy and photothermal therapy (created in BioRender.com). Abstract : Chemotherapy is a conventional treatment method for metastatic bone cancer, but it has limitations, such as lower drug-targeting of bone tissues and serious side effects. Bone metastasis almost always occurs in advanced cancer, and most patients in this period have strong drug resistance, which further worsens the curative effect. To address the above-mentioned difficulties, a drug delivery platform is proposed in this paper that accomplishes the bone-targeting of drugs to efficiently inhibit tumors. First, the anti-cancer drugs 5-fluorouracil (5-Fu) and indocyanine green (ICG) were loaded into a zeolitic imidazolate framework (ZIF-90) to form 5-Fu/ICG@ZIF-90. Polyethylene glycol with zoledronic acid (ZOL) was encapsulated using 5-Fu/ICG@ZIF-90 to synthesize 5-Fu/ICG@ZIF-90-PEG-ZOL nanoparticles, which showed dimensional stability, good thermal stability, and bone-targeting ability. Second, the in vitro anti-cancer activity of the designed platform was investigated using cytotoxicity, apoptosis, live–dead staining, cell cycle, and cell ultrathin section analysis. The results indicated that the nanoparticles inhibited MCF-7 cell activity when chemotherapy was combined with PTT. Finally, H&E staining and TUNEL detection were performed in mouse organs and tumors. The nanoparticles combined with photothermal therapy (PTT) and triggered by near-infrared irradiation induce apoptosis of tumor cells in vivo, displaying a better efficacy of combined chemotherapy and photothermal therapy. Experiments conducted on the 5-Fu/ICG@ZIF-90-PEG-ZOL nanoparticles demonstrated their promising performance for cancer bone metastasis inhibition. … (more)
- Is Part Of:
- Biomaterials science. Volume 10:Number 7(2022)
- Journal:
- Biomaterials science
- Issue:
- Volume 10:Number 7(2022)
- Issue Display:
- Volume 10, Issue 7 (2022)
- Year:
- 2022
- Volume:
- 10
- Issue:
- 7
- Issue Sort Value:
- 2022-0010-0007-0000
- Page Start:
- 1831
- Page End:
- 1843
- Publication Date:
- 2022-03-07
- Subjects:
- Biomedical materials -- Periodicals
610.28 - Journal URLs:
- http://pubs.rsc.org/en/journals/journalissues/bm ↗
http://www.rsc.org/ ↗ - DOI:
- 10.1039/d1bm01717a ↗
- Languages:
- English
- ISSNs:
- 2047-4830
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 2087.724000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 21192.xml